These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30264191)

  • 1. [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria].
    Mischnik A; Lübbert C; Mutters NT
    Internist (Berl); 2018 Dec; 59(12):1335-1343. PubMed ID: 30264191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
    Wright H; Bonomo RA; Paterson DL
    Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria].
    Probst-Kepper M; Geginat G
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Jul; 53(7-08):529-542. PubMed ID: 30036899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for multidrug-resistant Gram-negatives in urinary tract infections.
    Zollner-Schwetz I; König E
    Curr Opin Urol; 2023 May; 33(3):173-179. PubMed ID: 36861769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives.
    Karvouniaris M; Pontikis K; Nitsotolis T; Poulakou G
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):825-844. PubMed ID: 33270485
    [No Abstract]   [Full Text] [Related]  

  • 14. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
    Falcone M; Paterson D
    J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it time to move away from polymyxins?: evidence and alternatives.
    Soman R; Bakthavatchalam YD; Nadarajan A; Dwarakanathan HT; Venkatasubramanian R; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):461-475. PubMed ID: 33009595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study.
    Strich JR; Mishuk A; Diao G; Lawandi A; Li W; Demirkale CY; Babiker A; Mancera A; Swihart BJ; Walker M; Yek C; Neupane M; De Jonge N; Warner S; Kadri SS;
    Ann Intern Med; 2024 May; 177(5):559-572. PubMed ID: 38639548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M
    Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.